Top

Published in:

01-02-2022 | Ticagrelor

Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective

Authors: Mohammed A. Abosheasha, Afnan H. El-Gowily, Abdo A. Elfiky

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2022

Abstract

SARS-CoV-2 represents the causative agent of the current pandemic (COVID-19). The drug repurposing technique is used to search for possible drugs that can bind to SARS-CoV-2 proteins and inhibit viral replication. In this study, the FDA-approved antiplatelets are tested against the main protease and spike proteins of SARS-CoV-2 using in silico methods. Molecular docking and molecular dynamics simulation are used in the current study. The results suggest the effectiveness of vorapaxar, ticagrelor, cilostazol, cangrelor, and prasugrel in binding the main protease (M^pro) of SARS-CoV-2. At the same time, vorapaxar, ticagrelor, and cilostazol are the best binders of the spike protein. Therefore, these compounds could be successful candidates against COVID-19 that need to be tested experimentally.

Available only for authorised users

Paules CI, Marston HD, Fauci AS (2020) Coronavirus infections-more than just the common cold. JAMA 323(8):707–708. https://doi.org/10.1001/jama.2020.0757CrossRefPubMed

Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63(3):457–460. https://doi.org/10.1007/s11427-020-1637-5CrossRefPubMedPubMedCentral

Ramphul K, Mejias SG (2020) Coronavirus disease: a review of a new threat to public health. Cureus 12(3):e7276. https://doi.org/10.7759/cureus.7276CrossRefPubMedPubMedCentral

Elfiky AA (2021) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn 39(9):3204–3212. https://doi.org/10.1080/07391102.2020.1761882CrossRefPubMed

Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, McHugh TD, Memish ZA, Drosten C, Zumla A, Petersen E (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infectious diseases : IJID : official Publication Int Society for Infectious Dis 91:264–266. https://doi.org/10.1016/j.ijid.2020.01.009CrossRef

Salata C, Calistri A, Parolin C, Palu G (2019) Coronaviruses: a paradigm of new emerging zoonotic diseases. Pathog Dis. https://doi.org/10.1093/femspd/ftaa006CrossRefPubMed

Sohag AAM, Hannan MA, Rahman S, Hossain M, Hasan M, Khan MK, Khatun A, Dash R, Uddin MJ (2020) Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: a comprehensive review. Drug Dev Res. https://doi.org/10.1002/ddr.21709CrossRefPubMedPubMedCentral

Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA (2020) Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens (Basel, Switzerland) 9 (3). doi:https://doi.org/10.3390/pathogens9030186

Kumar Y, Singh H, Patel CN (2020) In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Public Health 13(9):1210–1223. https://doi.org/10.1016/j.jiph.2020.06.016CrossRefPubMedPubMedCentral

10.

Hilgenfeld R (2014) From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 281(18):4085–4096. https://doi.org/10.1111/febs.12936CrossRefPubMedPubMedCentral

11.

Mondal P, Natesh J, Abdul Salam AA, Thiyagarajan S, Meeran SM (2020) Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1842246CrossRefPubMedPubMedCentral

12.

Maldonado E, Tao D, Mackey K (2020) Antithrombotic therapies in COVID-19 disease: a systematic review. J Gen Intern Med 35(9):2698–2706. https://doi.org/10.1007/s11606-020-05906-yCrossRefPubMedPubMedCentral

13.

Monteleone G, Sarzi-Puttini PC, Ardizzone S (2020) Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol 2(5):e255–e256. https://doi.org/10.1016/S2665-9913(20)30092-8CrossRefPubMedPubMedCentral

14.

Giani M, Seminati D, Lucchini A, Foti G, Pagni F (2020) Exuberant plasmocytosis in bronchoalveolar lavage specimen of the first patient requiring extracorporeal membrane oxygenation for SARS-CoV-2 in Europe. J Thoracic Oncol: official Publication International Association for the Study of Lung Cancer 15(5):e65–e66. https://doi.org/10.1016/j.jtho.2020.03.008CrossRef

15.

Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147. https://doi.org/10.1016/j.thromres.2020.04.013CrossRefPubMedPubMedCentral

16.

Kow CS, Hasan SS (2021) Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta-analysis. J Thromb Thrombolysis 52(1):124–129. https://doi.org/10.1007/s11239-021-02436-0CrossRefPubMedPubMedCentral

17.

Corrochano M, Acosta-Isaac R, Mojal S, Miqueleiz S, Rodriguez D, Quijada-Manuitt MA, Fraga E, Castillo-Ocana M, Amaro-Hosey K, Albiol N, Soria JM, Antonijoan RM, Souto JC (2021) Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-021-02507-2CrossRefPubMedPubMedCentral

18.

Mycroft-West C, Su D, Elli S, Li Y, Guimond S, Miller G, Turnbull J, Yates E, Guerrini M, Fernig D, Lima M, Skidmore M (2020) The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. BioRxiv. https://doi.org/10.1101/2020.02.29.971093CrossRef

19.

Mahmud S, Elfiky AA, Amin A, Mohanto SC, Rahman ME, Acharjee UK, Saleh MA (2021) Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: an in silico perspective. Futur Virol 16(7):467–474. https://doi.org/10.2217/fvl-2020-0233CrossRef

20.

Gyebi GA, Elfiky AA, Ogunyemi OM, Ibrahim IM, Adegunloye AP, Adebayo JO, Olaiya CO, Ocheje JO, Fabusiwa MM (2021) Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum. Comput Biol Med 136:104671. https://doi.org/10.1016/j.compbiomed.2021.104671CrossRefPubMedPubMedCentral

21.

Sonousi A, Mahran HA, Ibrahim IM, Ibrahim MN, Elfiky AA, Elshemey WM (2021) Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective. Pharmacol Rep. https://doi.org/10.1007/s43440-021-00300-9CrossRefPubMedPubMedCentral

22.

Elfiky AA, Ibrahim IM, Amin FG, Ismail AM, Elshemey WM 2021 COVID-19 and Cell Stress. In: Rezaei N (ed) Coronavirus Disease - COVID-19. Springer International Publishing, Cham, pp 169–178. doi:https://doi.org/10.1007/978-3-030-63761-3_10

23.

Kupferschmidt K, Cohen J (2020) Race to find COVID-19 treatments accelerates. Science 367(6485):1412–1413. https://doi.org/10.1126/science.367.6485.1412CrossRefPubMed

24.

Abosheasha MA, El-Gowily AH (2021) Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M(pro) and spike protein: drug repurposing approach. Drug Dev Res 82(2):217–229. https://doi.org/10.1002/ddr.21743CrossRefPubMed

25.

Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, Wang J, Yu B, Zhang J, Bryant SH (2016) PubChem substance and compound databases. Nucleic Acids Res 44(D1):D1202-1213. https://doi.org/10.1093/nar/gkv951CrossRefPubMed

26.

2.4.1 V The PyMOL Molecular Graphics System, Version 2.4.1 Schrödinger, LLC.

27.

Huang J, MacKerell AD Jr (2013) CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem 34(25):2135–2145. https://doi.org/10.1002/jcc.23354CrossRefPubMedPubMedCentral

28.

Mark P, Nilsson L (2001) Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J Phys Chem A 105(43):9954–9960CrossRef

29.

Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graphics 14(1):33–38. https://doi.org/10.1016/0263-7855(96)00018-5CrossRef

30.

Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26(16):1781–1802. https://doi.org/10.1002/jcc.20289CrossRefPubMedPubMedCentral

31.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612CrossRefPubMed

32.

Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461. https://doi.org/10.1002/jcc.21334CrossRefPubMedPubMedCentral

33.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791. https://doi.org/10.1002/jcc.21256CrossRefPubMedPubMedCentral

34.

Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein–ligand interaction profiler. Nucleic Acids Res 43(W1):W443–W447CrossRefPubMedPubMedCentral

35.

Khambholja K, Asudani D (2020) Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis 35:101710. https://doi.org/10.1016/j.tmaid.2020.101710CrossRefPubMedPubMedCentral

36.

Elfiky AA (2020) Corrigendum to "Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study" [Life Sci. 253 (2020) 117592]. Life Sci 258:118350. doi:https://doi.org/10.1016/j.lfs.2020.118350

37.

Elfiky AA (2020) Reply to a letter to the editor. Life Sci 252:117715. https://doi.org/10.1016/j.lfs.2020.117715CrossRefPubMedPubMedCentral

38.

Parvathaneni V, Gupta V (2020) Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. Life Sci 259:118275. https://doi.org/10.1016/j.lfs.2020.118275CrossRefPubMedPubMedCentral

39.

Baker NC, Lipinski MJ, Lhermusier T, Waksman R (2014) Overview of the 2014 food and drug administration cardiovascular and renal drugs advisory committee meeting about vorapaxar. Circulation 130(15):1287–1294. https://doi.org/10.1161/CIRCULATIONAHA.114.011471CrossRefPubMed

40.

group As, (2018) Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. The lancet HIV 5(10):e553–e559. https://doi.org/10.1016/S2352-3018(18)30214-5CrossRef

41.

Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug metabolism and disposition: the biological fate of chemicals 38(9):1514–1521. https://doi.org/10.1124/dmd.110.032250CrossRef

42.

Dorsam RT, Kunapuli SP (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113(3):340–345. https://doi.org/10.1172/JCI20986CrossRefPubMedPubMedCentral

43.

Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J (2001) Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19(4):369–386. https://doi.org/10.1111/j.1527-3466.2001.tb00076.xCrossRefPubMed

44.

Elfiky AA, Ibrahim IM (2021) Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico. J Infect 82(5):186–230. https://doi.org/10.1016/j.jinf.2021.01.015CrossRefPubMedPubMedCentral

45.

Ibrahim MI, Elfiky AA, Elgohary AM (2021) Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective. Biochem Biophys Res Commun 562:89–93. https://doi.org/10.1016/j.bbrc.2021.05.058CrossRefPubMedPubMedCentral

46.

Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA (2020) COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect 80(5):554–562. https://doi.org/10.1016/j.jinf.2020.02.026CrossRefPubMedPubMedCentral

47.

Elfiky AA (2020) SARS-CoV-2 spike-heat shock protein A5 (GRP78) recognition may be related to the immersed human coronaviruses. Front Pharmacol 11:577467. https://doi.org/10.3389/fphar.2020.577467CrossRefPubMedPubMedCentral

48.

Elfiky AA, Ibrahim IM, Ismail AM, Elshemey WM (2021) A possible role for GRP78 in cross vaccination against COVID-19. J Infect 82(2):282–327. https://doi.org/10.1016/j.jinf.2020.09.004CrossRefPubMed

49.

Ismail AM, Elfiky AA (2020) SARS-CoV-2 spike behavior in situ: a Cryo-EM images for a better understanding of the COVID-19 pandemic. Signal Transduct Target Ther 5(1):252. https://doi.org/10.1038/s41392-020-00365-7CrossRefPubMedPubMedCentral

Title: Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective
Authors: Mohammed A. Abosheasha
Afnan H. El-Gowily
Abdo A. Elfiky
Publication date: 01-02-2022
Publisher: Springer US
Keywords: Ticagrelor
SARS-CoV-2
Voraxapar
Prasugrel
COVID-19
Published in: Journal of Thrombosis and Thrombolysis / Issue 2/2022
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-021-02558-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

One-year clinical outcome of patients with left ventricular thrombus after acute myocardial infarction discharged on triple or dual antithrombotic therapy

Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma

Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone

Predicting factors for pulmonary embolism response team activation in a general pulmonary embolism population

Uncertainties about platelet function and genetic testing for guiding dual antiplatelet therapy in percutaneous coronary intervention

One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage